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Abstract
Background: The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major
public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is
virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia.
Methods: At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based
on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient
elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence
to therapy was measured by pharmacy refill data.
Results: Out of 1303 patients, 328 (25.2%) fulfilled the treatment criteria and 254 (19.5%) had started tenofovir
disoproxil fumarate therapy prior to September 1, 2016. Of the patients who started therapy, 30 (11.8%) died
within the first year of follow-up (28 of whom had decompensated cirrhosis), 9 (3.5%) self-stopped treatment, 7
(2.8%) were lost to follow-up, and 4 (1.6%) were transferred out. In patients who completed 12 months of treatment,
the median Fibroscan value declined from 12.8 to 10.4 kPa (p < 0.001), 172 of 202 (85.1%) patients with available
pharmacy refill data had taken ≥ 95% of their tablets, and 161 of 189 (85.2%) patients with viral load results had
suppressed viremia. Virologic failure (≥ 69 IU/mL) at 12 months was associated with high baseline HBV viral load
(> 1,000,000 IU/mL; adjusted OR 2.41; 95% CI 1.04–5.55) and suboptimal adherence (< 95%; adjusted OR 3.43,
95% CI 1.33–8.88).
Conclusions: This pilot program demonstrated that antiviral therapy of CHB can be realized in Ethiopia with
good clinical and virologic response. Early mortality was high in patients with decompensated cirrhosis, underscoring
the need for earlier detection of hepatitis B virus infection and timely initiation of treatment, prior to the development
of irreversible complications, in sub-Saharan Africa.
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Background
Chronic infection with hepatitis B virus (HBV) is a
leading cause of cirrhosis, hepatic decompensation, and
hepatocellular carcinoma (HCC). Approximately 257
million people worldwide are living with chronic
hepatitis B (CHB), and an estimated 887,000 deaths per
year are attributable to HBV infection [1]. Despite an
effective vaccine and potent antiviral drugs, the number
of HBV-related deaths has increased by 33% between
1990 and 2013 [2]. Indeed, in 2015, viral hepatitis
claimed more lives than human immunodeficiency
virus (HIV) [3].
Studies from high-income countries have shown
that antiviral treatment of CHB reduces the risk of
disease progression [4]. Long-term antiviral treatment
has been shown to stop and even reverse liver fibrosis
and prevent development of HCC [5, 6]. Hepatitis B
surface antigen (HBsAg) loss is the optimal treatment
endpoint, but is rarely achieved; thus, most patients
need long-term treatment to suppress viral replication
and prevent hepatic complications [7].
In sub-Saharan Africa, treatment for viral hepatitis
is rarely available in the public sector. Patients with
CHB are left untreated and physicians are left to
merely follow the natural course of the disease and
provide palliative care. Paradoxically, the recom-
mended first-line drug for CHB, tenofovir disoproxil
fumarate (TDF), is registered in most African coun-
tries for the treatment of HIV, but not for hepatitis.
Therefore, patients mono-infected with HBV cannot
access life-saving treatment, whereas those with HIV/
HBV co-infection receive free treatment through
donor agencies.
In 2016, the World Health Organization (WHO)
published the Global Health Sector Strategy of Viral
Hepatitis [3] and set an ambitious goal of eliminating
viral hepatitis as a public health threat by 2030. To
meet the WHO goals, countries and regions should
reduce new infection by 90% and deaths by 65% by
2030 [3, 8]. However, to date, few African countries
have developed national action plans for viral hepa-
titis, and only one published study – the PROLIFICA
study in The Gambia [9] – has reported results of
HBV treatment on the continent. Consequently, there
is a lack of local data to direct guidelines and pro-
mote implementation.
Herein, we present results from one of the first and
largest public treatment programs for hepatitis B in
sub-Saharan Africa. Many of the barriers to treatment in
Ethiopia, such as lack of diagnostic facilities, absence of
public funding, and restrictions on antiviral drugs, are
shared by most low-income countries; therefore, we be-
lieve that our findings can be relevant in the global
scaling-up of antiviral treatment of CHB.
Methods
Study setting and participants
Ethiopia is a low-income country in East Africa with an
estimated prevalence of hepatitis B at 7.4% [10]. A pilot
program for the treatment of CHB was established in
February 2015 at St. Paul’s Hospital Millennium Medical
College, which is a referral hospital in the capital Addis
Ababa. A simplified approach to treatment and care of
individuals with CHB was employed, wherein transient
elastography rather than liver biopsy was used to assess
liver fibrosis, nurses rather than physicians were respon-
sible for most of the patient consultations, and treatment
eligibility criteria were straight-forward and easy to use.
As this was the first public healthcare facility offering
CHB treatment in the country, patients were referred
from various hospitals, health centers, blood banks, and
antenatal clinics for evaluation and treatment. Patients
aged 18 years or above with CHB, defined as a persist-
ently positive HBsAg test for more than 6 months, were
enrolled in the program. Since previous HBsAg testing
was usually performed in other hospitals or private
clinics, and often years back, we accepted the patients’
recollection of a previous positive result without de-
manding a written laboratory report. Patients who were
HIV positive at presentation were not included, but ra-
ther transferred to the nearest HIV care and treatment
center. Likewise, individuals with a known terminal dis-
ease such as HCC were referred for further management
elsewhere.
Patient assessment and laboratory tests
At enrollment, all patients were interviewed by a trained
nurse in their own language. A full diagnostic work-up
was performed, including laboratory tests and transient
elastography. The following laboratory tests were per-
formed at the first visit:
 Point-of-care rapid diagnostic tests: HBsAg, HIV
(further tests were not performed in patients found
to be HBsAg negative or HIV positive)
 Routine chemistry: complete blood count, bilirubin,
alanine aminotransferase (ALT), aspartate
aminotransferase (AST), creatinine
 Serology: HBsAg, hepatitis C virus (HCV) antibody,
hepatitis D virus (HDV) antibody
 HBV DNA viral load
Patients with signs or symptoms of decompensated
liver disease, such as ascites or jaundice, were scheduled
to see a physician within 1–2 weeks. These patients
would usually receive symptom-directed therapy such as
diuretics for ascites/edema; however, within our simpli-
fied setup, we did not systematically perform endoscopic
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treatment of esophageal varices or other more advanced
procedures.
Patients without signs or symptoms of advanced liver
disease were appointed to a physician after 3 months
when the viral load result would usually be available.
The decision to start therapy was made by a physician
using the predefined criteria given below; otherwise, the
follow-up was nurse led.
Those who started antiviral therapy were followed-up
after 2 and 4 weeks, and thereafter 3-monthly. The main
focus at each visit was adherence counseling (including
pill count) and monitoring for side effects. Untreated in-
dividuals were followed-up at 3-month intervals.
The following laboratory tests were performed during
follow-up (tests in parenthesis were only performed in
patients on treatment):
 3-monthly: complete blood count, ALT, AST,
(creatinine, HIV rapid test)
 6-monthly: HBsAg, HBV viral load
Blood tests were performed using commercially avail-
able kits and assays. HBsAg was detected on-site using a
WHO-approved rapid diagnostic test (Determine, Alere
Inc., USA). HIV testing was done in accordance with the
National algorithm, i.e., using a WHO-approved rapid
test kit (HIV 1+2 Antibody Colloidal Gold [KHB],
Shanghai Kehua Bio-engineering co., China) for screen-
ing, and another rapid test kit (HIV 1/2 STAT-PAK,
Chembio Diagnostics, USA) for confirmation. Other
routine laboratory investigations for hematology (Huma-
Count 30, Human, Germany), biochemistry (Humalyzer
3000, Human, Germany), and serology (Elisys Uno, Hu-
man, Germany) were performed locally.
Aspartate aminotransferase to platelet ratio index
(APRI) and FIB-4 were derived from standard blood test
results using the following formulas:
APRI : AST U=L½ =upper limit of normal for ASTð Þ
=platelet count 109=L
  100
FIB−4 : age years½   AST U=L½ ð Þ=
platelet count 109=L
  ALT U=L½ ð Þ1=2
 
HBV viral load testing was unavailable in Ethiopia at
the time the program was set up; thus, baseline viral
load testing was performed after shipment of samples to
the Norwegian Public Health Institute (Oslo, Norway).
The Abbott RealTime HBV assay (Abbott Molecular,
Des Moines, USA) was used, following the manufac-
turer’s instructions. From 2016, HBV viral load testing
was established at a private laboratory in Addis Ababa
using the Abbott RealTime HBV assay and therefore all
follow-up samples for HBV viral load monitoring were
tested locally.
HDV antibodies were detected using an enzyme-linked
immunosorbent assay (ELISA) method (ETI-AB-DEL
TAK-2, Diasorin, Italy) from EDTA plasma samples. A sec-
ond anti-HDV ELISA assay (Dia.Pro Diagnostic Bioprobes
Srl, Milan, Italy) was used to confirm indeterminate or
weak positive results obtained with the Diasorin assay, as
suggested by the manufacturer when plasma is used instead
of serum. These analyses were performed at the Centre na-
tional de référence des hépatites B, C et Delta, Hôpitaux
universitaires de Paris-Seine-Saint-Denis, France.
Liver fibrosis assessment
Liver fibrosis was assessed using transient elastography
(Fibroscan 402, Echosense, France). Patients were
instructed to fast for at least 2 h prior to the examin-
ation, and the procedure was performed by an experi-
enced operator as per the manufacturer’s instructions.
The median of 10 readings was employed, and the result
was discarded if the interquartile range (IQR) divided by
the median exceeded 30%.
Based on a previous meta-analysis and a study from
West Africa [11, 12], we used a Fibroscan threshold of
7.9 kPa to define significant fibrosis (corresponding to
Metavir score ≥ F2) and 9.9 kPa to define cirrhosis (cor-
responding to Metavir score F4). Ultrasound of the liver
was performed at baseline, and thereafter annually, in all
patients who started treatment, mainly to detect HCC.
Treatment eligibility
Since this program opened prior to the launch of the
WHO Hepatitis B Guidelines in 2015 [13], treatment eli-
gibility criteria were based on the European Association
for the Study of the Liver (EASL) Guidelines from 2012
[7], with some modifications. Specifically, since liver bi-
opsy was unrealistic in this setting, the two EASL cri-
teria pertaining to liver inflammation (Metavir ≥A2 with
viral load > 2000 IU/mL and ALT > 80 U/L with viral
load > 20,000 IU/mL) were merged into one, namely
ALT > 80 U/L with viral load > 2000 IU/mL. Further-
more, since African patients with CHB are at particular
risk of HCC, we created a new criterion for patients with
HCC in their close family.
Thus, patients who fulfilled the following criteria were
considered eligible for treatment:
1) Decompensated cirrhosis
2) Compensated cirrhosis (confirmed with ultrasound
and/or Fibroscan)
3) Significant fibrosis (Fibroscan > 7.9 kPa) and viral
load > 2000 IU/mL
4) Moderate/severe liver inflammation (ALT > 80 U/L)
and viral load > 2000 IU/mL
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5) HCC among first-degree relatives and viral load
> 2000 IU/mL
Patients who met the treatment criteria were given ad-
herence counseling and educated about the disease and
the need for life-long follow-up. Preventive measures
were recommended, including HBV vaccination to the
patients’ partner and children. Based on its potency,
safety profile, and high barrier to resistance, TDF
(Viread, Gilead Sciences, lnc., Foster City, CA, USA) 300
mg once daily was used in this program. Treatment for
HCV and HDV co-infections were not available through
this program.
Assessment of adherence to therapy
In patients who started antiviral treatment, TDF was ini-
tially dispensed for 1 month’s duration, and thereafter at
3-monthly intervals. At each visit to the clinic, the pa-
tients were told to bring their old pill boxes so that the
remaining pills could be counted. Adherence was calcu-
lated by dividing the total amount of tablets dispensed
by the total number of days since initiating therapy,
expressed as percentage. This method (‘pharmacy refill’
or ‘pill count’) has previously been proven accurate in
HIV programs in resource-limited settings [14].
Statistical analysis
Baseline characteristics were summarized using descrip-
tive statistics. Groups were compared using χ2 tests for
categorical and Mann–Whitney U-tests for continuous
variables. Changes over time in levels of ALT, viral load,
and transient elastography were compared using Wil-
coxon signed-rank tests. Intra-individual changes in
Fibroscan measurements of more than 20% were consid-
ered significant [15].
Logistic regression models were used to study associa-
tions between baseline variables and clinically relevant
outcomes (adherence, virologic failure, death). Variables
with a p value below 0.2 in univariable analyses were in-
cluded in multivariable logistic regression models, using
a forward stepwise method. HBV viral load < 69 IU/mL
was considered as viral suppression to allow comparison
with previous CHB studies [6, 16], and > 1000 IU/mL
was considered as major virologic failure.
SPSS version 23.0 software (SPSS Inc., Chicago, IL,
USA) was used to analyze the data. The level of signifi-
cance was set at p < 0.05. Results were reported in ac-
cordance with the Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) state-
ment guidelines [17].
Ethics
The study was approved by the National Research
Ethics Review Committee (Ref. No.: 3.10/829/07) in
Ethiopia and by the Regional Committees for Medical
and Health Research Ethics (Ref. No.: 2014/1146) in
Norway. The study was conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from all study subjects.
Results
Patient characteristics
Between February 9 and December 14, 2015, a total of
1303 adults with CHB were enrolled in the program. Of
these, 328 (25.2%) fulfilled the treatment criteria and
254 (19.5%) started treatment prior to September 1,
2016 (Fig. 1). Compared to those who were ineligible for
treatment, individuals who met the treatment eligibility
criteria were more likely to be men, older, anti-HDV
positive, and to have elevated ALT, high viral load and
increased liver stiffness (Table 1). Patients eligible for
treatment but who did not start it were more likely to
have a normal liver stiffness (< 8.0 kPa, 28.6 vs. 10.5%,
p < 0.001) and a lower APRI score (median 0.31 vs. 0.54,
p = 0.013) compared to those who started treatment;
other distinguishing features could not be identified.
Among those who started treatment, 197 (77.6%) were
men and the median age was 35 years (IQR 27–42). The
majority (n = 137, 53.9%) were from the capital city,
Addis Ababa. The median ALT at baseline was 36 U/L
(IQR 24–50), the median viral load was 26,700 IU/mL
(IQR 568–9,480,000), and the median Fibroscan value
was 15.5 kPa (IQR 9.0–28.9).
Antiviral treatment
Most patients in this cohort started treatment based on
a diagnosis of cirrhosis. A total of 105 (41.3%) patients
had clinical ascites or a history of ascites and were
classified as decompensated cirrhosis, whereas 81
(31.9%) patients without ascites had a Fibroscan value
above 9.9 kPa and were classified as compensated cir-
rhosis. The remaining started treatment based on sig-
nificant liver fibrosis (n = 30, 11.8%), moderate/severe
liver inflammation (n = 14, 5.5%), HCC in a first-degree
relative (n = 3, 1.2%), or other criteria (n = 21, 8.3%).
The latter groups mainly comprised patients who had
initiated treatment through the private sector or
‘black market’, and who could not be assessed using
the standard criteria, since most of had suppressed
viral load at enrollment.
Among patients who initiated treatment, 111 (43.7%)
started immediately (i.e., within 4 weeks of enrollment),
mainly due to decompensated cirrhosis, whereas 116
(45.7%) started treatment between 1 and 6 months of
enrollment. Only 27 (10.6%) started later than 6 months
after enrollment.
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Treatment response
Overall, 30 (11.8 %) patients died within the first 12
months after starting antiviral treatment, 28 of whom
had decompensated cirrhosis at baseline. Among the de-
compensated patients, neither sex (men vs. women; odds
ratio (OR) 1.54, 95% confidence interval (CI) 0.40–5.91,
p = 0.531), age (per 1-year increment; OR 1.01, 95% CI
0.97–1.06, p = 0.549), nor co-infections (HCV and/or
HDV; OR 1.11, 95% CI 0.20–6.06, p = 0.906) predicted
subsequent death.
Another 20 (7.9%) patients failed to complete 12
months of TDF therapy; 7 (2.8%) were lost to follow-up,
9 (3.5%) refused to continue treatment for various rea-
sons, and 4 (1.6 %) were transferred out. In the latter
group, 3 were diagnosed with HCC and transferred to
palliative care, and 1 was diagnosed with HIV on her
3-month follow-up visit and transferred to HIV care.
Baseline characteristics of the 3 patients who developed
HCC are summarized in Table 2.
Among the remaining 204 patients who completed 1
year of antiviral treatment, the median ALT was 36 U/L
(IQR 24–47) at baseline and 32 U/L (IQR 24–39) at 12
months (p = 0.062), and the median Fibroscan value was
12.8 kPa (IQR 8.8–23.6) at baseline and 10.4 kPa
(IQR 6.8–17.4) at 12 months (p < 0.001). A total of 140
patients had paired Fibroscan results at baseline and 12
months for comparison; the median intra-individual im-
provement in liver stiffness at 12 months was 3.4 kPa
Fig. 1 Profile of the hepatitis B treatment program, Addis Ababa, Ethiopia. CHB chronic hepatitis B
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(IQR 0.4–7.0) (Fig. 2). After 12 months of treatment, 83
(59.3%) patients had a significant improvement in liver
stiffness, 41 (29.3%) were unchanged (< 20% change from
baseline), and 16 (11.4%) deteriorated.
Five individuals (2.5%) experienced HBsAg loss, i.e.,
they had two consecutively negative HBsAg results; 4 of
these developed anti-HBs antibodies. In retrospect, how-
ever, 2 cases might have been acute hepatitis B since
HBsAg positivity 6 months prior to inclusion could not
be documented.
Out of 189 patients who had a viral load test performed
at 12 months, 161 (85.2%) had suppressed viremia
(i.e., <69 IU/mL) and only 6 (3.2%) had major virologic
failure (i.e., > 1000 IU/mL). Genotypic resistance testing
was performed in these 6 samples; 3 had wild type virus
and 3 failed amplification due to low viral loads. The
proportion of patients with suppressed viremia at 6
and 12 months is given in Fig. 3. Virologic failure
(i.e., ≥ 69 IU/mL) at 12 months was associated with high
baseline HBV viral load (> 1,000,000 IU/mL) and subopti-
mal adherence (< 95%) (Table 3).
TDF therapy was generally well tolerated and only one
individual with underlying comorbidities (diabetes melli-
tus, hypertension, gout, cardiomyopathy, alcohol abuse)
Table 1 Baseline characteristics of patients enrolled in a pilot treatment program for chronic hepatitis B, Addis Ababa, Ethiopia
All patients
(n = 1303)
Eligible for treatment
(n = 328)
Not eligible for treatment
(n = 962)a
Number (%) Number (%) Number (%) P
Men 770 (59.1) 260 (79.3) 500 (52.0) < 0.001
Age (years) 0.006
18–25 286 (21.9) 64 (19.5) 220 (22.9)
26–35 549 (42.1) 122 (37.2) 424 (44.1)
36–45 289 (22.2) 83 (25.3) 202 (21.0)
> 45 179 (13.7) 59 (18.0) 116 (12.1)
Marital status 0.667
Single 457 (35.1) 117 (35.7) 338 (35.1)
Married 796 (61.1) 201 (61.3) 584 (60.7)
Divorced/widowed 50 (3.8) 10 (3.0) 40 (4.2)
ALT, U/Lb < 0.001
< 40 1014 (78.9) 185 (57.3) 818 (86.2)
40–79 201 (15.6) 91 (28.2) 108 (11.4)
≥ 80 70 (5.4) 47 (14.6) 23 (2.4)
HBV viral load, IU/mLc < 0.001
< 2000 722 (56.5) 107 (33.1) 608 (64.5)
2000–19,999 256 (20.0) 46 (14.2) 208 (22.1)
≥ 20,000 301 (23.5) 170 (52.6) 127 (13.5)
Transient elastography, kPad < 0.001
< 8.0 879 (74.0) 46 (15.0) 825 (94.5)
8.0–9.9 67 (5.6) 39 (12.7) 27 (3.1)
≥ 10.0 242 (20.4) 221 (72.2) 21 (2.4)
Co-infections
Anti-HCV positive 28 (2.1) 7 (3.2) 21 (2.6) 0.619
Anti-HDV positive 19 (1.4) 10 (5.9) 9 (1.0) < 0.001
APRI, median (IQR)e 0.24 (0.17–0.36) 0.48 (0.27–0.90) 0.21 (0.16–0.29) < 0.001
FIB-4, median (IQR)f 0.56 (0.41–0.79) 1.06 (0.61–1.91) 0.55 (0.41–0.76) < 0.001
ALT alanine aminotransferase, HBV hepatitis B virus, HCV hepatitis C virus, HDV hepatitis D virus, APRI aspartate aminotransferase to platelet ratio index, IQR
interquartile range
a13 patients were already on treatment and could not be assessed for treatment eligibility
b18 results missing
c 24 results missing
d111 results missing
e124 results missing
f128 results missing
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discontinued due to progressive worsening of renal func-
tion. This patient was under treatment with several
drugs, including diuretics and an angiotensin-converting
enzyme inhibitor, and the role of TDF in the develop-
ment of renal failure remains unclear.
Adherence
Pharmacy refill data was available for 202 out of 204 pa-
tients who completed 12 months of antiviral treatment.
Out of these, 172 (85.1%) individuals had excellent adher-
ence, i.e., they took more than 95% of their tablets; 24
(11.9%) had medium adherence, i.e., they took between 80
and 95% of their tablets; and 6 had poor adherence,
i.e., they took less than 80% of their tablets. Neither
sex (men vs. women; OR 1.67, 95% CI 0.60–4.62, p = 0.326),
age (per 1-year increment; OR 0.98, 95% CI 0.94–1.02,
p = 0.221), nor decompensated liver disease (OR 1.11,
95% CI 0.20–6.06, p = 0.906) were significantly associated
with suboptimal adherence (i.e., < 95%).
Discussion
This report summarizes 1-year treatment results from
the largest published cohort of CHB patients in
sub-Saharan Africa. The findings indicate that antiviral
treatment can be delivered safely and effectively in a
low-income setting like Ethiopia using a simplified ap-
proach, similar to the early experiences from HIV treat-
ment programs on the continent. In our own setup, the
day-to-day management of patients, including the initial
patient interview, liver stiffness measurement, blood
testing and patient education, was performed by trained
nurses, whereas physicians were involved only in the ac-
tual decision to start therapy and in the management of
complications. Such task shifting, from physicians to
trained nurses, has been successful in HIV programs
throughout Africa [18], and may also prove useful in the
management of other chronic infections like CHB.
The estimated 1-year mortality among patients who
started treatment was 11.8%. The high early mortality
likely reflects the absence of treatment options for CHB in
the country to date; thus, patients with advanced cirrhosis,
who are desperate for treatment, might have been
overrepresented in our cohort. Indeed, 28 of 30 patients
who died had decompensated cirrhosis at enrollment. On
the other hand, approximately three-quarters of patients
with decompensated cirrhosis in our study were still alive
after 12 months of TDF treatment. These results are in
line with a study from Korea [19], where 1-year
transplantation-free survival was of 87.1% among 70 pa-
tients with decompensated cirrhosis treated with enteca-
vir, suggesting that treatment of this group is safe and
Table 2 Characteristics of patients who developed hepatocellular
carcinoma during the initial 12 months of antiviral treatment
Baseline characteristics Patient 1 Patient 2 Patient 3
Sex F M M
Age 65 55 50
ALT, U/L 81 30 110
HBV viral load, IU/mL 75 13 10,100
Transient elastography, kPa 29.0 20.6 75.0
Co-infection (HCV/HDV) No No HDV
Co-morbidity No IDDM IDDM
Previous antiviral therapy No No No
Decompensated liver disease No Yes Yes
ALT alanine aminotransferase, HBV hepatitis B virus, HCV hepatitis C virus,
HDV hepatitis D virus, IDDM insulin-dependent diabetes mellitus
Fig. 2 Change in liver stiffness among patients who completed 12 months of hepatitis B treatment
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beneficial. Clearly, however, a major challenge in the Ethi-
opian setting is the identification of HBV-infected individ-
uals earlier in the course of their illness, prior to the
development of severe complications. This would require
better access to HBV testing and screening, and improved
access to antiviral therapy throughout the country.
In our study, 85.2% of patients achieved viral suppres-
sion 12 months after treatment initiation. Only 6 patients
had major virologic failure and no genotypic resistance
was discovered. This is comparable to studies from
high-income settings. Indeed, in the phase 3 study of TDF
supported by Gilead Sciences, viral suppression below 69
IU/mL was achieved in 76% and 93% of HBeAg-positive
and HBeAg-negative patients, respectively [16]. Moreover,
in a real-life multicenter study of 302 CHB patients from
19 countries in Europe, 68% of HBeAg-positive patients
and 90% HBeAg-negative patients treated with TDF had a
suppressed viral load after 12 months [20]. Studies from
low- and middle-income countries are scarce, but in a
retrospective study involving 220 cirrhotic patients from
India [21], 91.8% had suppressed viremia after 12 months
treatment with TDF. Furthermore, in a large real-life study
from 50 sites in China [22], viral suppression after 12
months treatment with entecavir was achieved in 64% of
patients with compensated liver disease and 68% with de-
compensated liver disease. Of note, detectable viremia at
12 months does not necessarily imply treatment failure,
since it might take longer than 12 months to achieve full
viral suppression in individuals with very high baseline
viral loads [20].
Interestingly, liver stiffness (measured by Fibroscan)
improved significantly during the initial 12 months of
therapy. Reversal of liver fibrosis during antiviral therapy
has previously been described by Marcellin et al. [6], who
reported a significant improvement in fibrosis scores in
repeated liver biopsies after 1 and 5 years of TDF treat-
ment. Whether histological improvement translates to re-
duced risk of HCC and death has yet to be proven in
Africa, but experiences from other settings indicate that
antiviral treatment significantly reduces the risk of these
complications [5].
The program loss in the present study was relatively
low; overall, 6.3% were lost to follow-up or self-stopped
Table 3 Predictors of virologic failure (HBV viral load ≥ 69 IU/mL) after 12 months of antiviral treatment, Addis Ababa, Ethiopia
Baseline variable Total (n = 189) Virologic failure (n = 28) Crude Adjusted
n (%) n (%) OR (95% CI) p OR (95% CI) p
Sex
Women 44 (23.3) 5 (17.9) 1
Men 145 (76.7) 23 (82.1) 1.52 (0.54–4.26) 0.426
Age, years (per 1-year increment) 35 (26–41)a 35 (26–41) a 1.00 (0.96–1.04) 0.952
Decompensated liver disease
No 126 (66.7) 20 (71.4) 1
Yes 63 (33.3) 8 (28.6) 0.77 (0.32–1.86) 0.563
HBV viral load, IU/mLb
≤ 106 116 (62.0) 12 (42.9) 1 1
> 106 71 (38.0) 16 (57.1) 2.52 (1.11–5.71) 0.026 2.41 (1.04–5.55) 0.039
Adherencec
≥ 95% 160 (85.1) 19 (67.9) 1 1
< 95% 28 (14.9) 9 (32.1) 3.74 (1.47–9.49) 0.006 3.43 (1.33–8.88) 0.011
HBV hepatitis B virus, OR odds ratio, CI confidence interval
aMedian (interquartile range)
bTwo missing values
cOne missing value
Fig. 3 Virologic response to therapy during the first 12 months of
antiviral treatment
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treatment. Although the follow-up time in our study was
shorter, this drop-out rate was lower than results from a
recent multicenter study in Germany involving 33 sites
across the country [23], where 75% remained in the
study after 36 months of TDF treatment. In the only
previous publication of CHB treatment in sub-Saharan
Africa [9], there was no program loss after 12 months;
however, the numbers were small.
Adherence to therapy was high in this cohort; 85.1% of
patients took at least 95% of their medication; this is in
line with studies from high-income countries. In a study
from USA [24], non-adherence was reported in 10–12%
of patients after 4 years of HBV therapy, whereas a study
from France found non-adherence among 7% of patients
after at least 3 months of CHB treatment [25]. High ad-
herence is a prerequisite to achieve the clinical benefits of
therapy and to avoid resistance; however, contrary to
first-generation anti-HBV drugs, resistance does not seem
to be a significant problem with TDF [26]. Previous stud-
ies from HIV programs have found that adherence rates
in Africa are at least as good as in North America or Eur-
ope [27]; our study suggests that the same appears to be
true for CHB treatment.
In the present program, treatment decisions were based
on viral load testing and liver stiffness measurements.
However, in most countries in sub-Saharan Africa, these
tests are practically unavailable. Although the WHO rec-
ommends the initiation of treatment based on clinical and
laboratory markers such as the APRI, experiences from
our cohort shows that this marker fails to detect 90% of
those in need of treatment [28]. Transient elastography,
on the contrary, has shown excellent agreement with liver
biopsy [29], and is non-invasive and easy to use, making it
an appealing tool in resource-limited settings. Neverthe-
less, the retail price of a Fibroscan machine is currently
beyond the budget of most low-income settings, for which
generic competition or other financial mechanisms to im-
prove access to this technology is an urgent priority.
With regard to viral load measurements, we have previ-
ously shown that dried blood spots can be used to reliably
quantify HBV DNA [30], which means that samples can
be sent to a central facility from smaller centers through-
out the country. Additionally, the recent development of
point-of-care molecular assays for various pathogens rep-
resent a new era of near-patient testing, and GeneXpert
(Cepheid, Sunnyvale, CA, USA) is expected to launch
their HBV DNA viral load kit later in 2018 (personal com-
munication, Emiliano Leone, Cepheid). Improved access
to low-cost, robust, point-of-care diagnostics will be a pre-
requisite to achieve the WHO goal of treating 80% of eli-
gible persons with CHB within 2030 [3]. However,
reaching this goal will also require concerted action from
international stakeholders and local ministries of health to
establish adequate funding mechanisms, develop local
treatment guidelines, and remove legislative barriers to
generic antiviral drugs.
Our study had certain limitations. First, although the
treatment program was set up at a local public hospital,
external financial support was provided to purchase a
Fibroscan device and run viral load testing. Nevertheless,
the clinic was run exclusively with local staff, most of
whom had no previous experience with hepatitis B man-
agement, and we believe the setup can be duplicated in
other countries in sub-Saharan Africa. Second, since this
was the first treatment center for CHB in the country,
patients with symptomatic (i.e., decompensated) liver
disease were overrepresented. The high early mortality
in the program reflects this, and as treatment becomes
more accessible mortality can be expected to decline.
Conclusion
The current pilot study showed that treatment for CHB
can be successful in terms of adherence to therapy and
retention in care. Furthermore, there was significant im-
provement in liver stiffness during the initial 12 months
of treatment, with the majority of patients achieving
viral suppression. However, initial mortality was high,
given that many patients presented with advanced cir-
rhosis. Therefore, earlier detection of HBV infection and
timely initiation of treatment – prior to the development
of irreversible complications – is needed to reach the
WHO goal of eliminating viral hepatitis as a public
health threat by 2030. This pilot program can provide
valuable information for other African countries aiming
to expand access to antiviral treatment of CHB.
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